WHO ICTRP trial
A multicenter, randomized, double-blind, placebo, parallel controlled clinical…
ChiCTR2400080348 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2400080348 |
|---|---|
| Public title | A multicenter, randomized, double-blind, placebo, parallel controlled clinical trial study on traditional Chinese medicine treatment in the recovery period of COVID-19 infection population |
| Scientific title | A multicenter, randomized, double-blind, placebo, parallel controlled clinical trial study on traditional Chinese medicine treatment in the recovery period of COVID-19 infection population |
| Primary sponsor | The Affiliated Hospital of Hunan Academy of Chinese Medicine |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 1 |
| Countries | China |
| Conditions | Recovery from COVID-19 infection |
| Interventions | experimental group:According to the type of syndrome, the subjects were given Gubenfuyuan granule and Sanshen Laifu respectively Granule or Shenling Fukang granule.;control group:At the same time, simulants with the same packaging, dosage… |
| Registration date | Jan 26, 2024 |
| Target size | experimental group:200;control group:200 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: